Daily Newsletter

06 February 2024

Daily Newsletter

06 February 2024

Incyte acquires global rights to MorphoSys’ tafasitamab

MorphoSys is entitled to a one-time payment of $25m from Incyte.

Vishnu Priyan February 06 2024

Incyte has acquired sole worldwide rights to tafasitamab, a humanised Fc-modified CD19-targeting immunotherapy, through an asset purchase agreement with MorphoSys.

The deal grants Incyte complete control of the development and commercialisation of tafasitamab worldwide.

MorphoSys is entitled to receive a one-time payment of $25m from Incyte.

The arrangement supersedes a previous collaboration between the two companies entered in 2020, which involved shared responsibilities for tafasitamab in the US.

Incyte will now independently manage all marketing and clinical development activities and MorphoSys will receive no further milestone payments, profit splits or royalties.

Tafasitamab is marketed as Monjuvi in the US and as Minjuvi elsewhere in the world. It is currently approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The drug is also undergoing clinical trials for other indications, including first-line DLBCL, relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Originally licensed from Xencor in 2010, tafasitamab incorporates an XmAb-engineered Fc domain, enhancing its ability to induce B-cell lysis through immune effector mechanisms. XmAb is a trademark of Xencor.

In the US, Monjuvi is approved in combination with lenalidomide for specific DLBCL patients not eligible for autologous stem cell transplant.

In Europe, Minjuvi has received conditional marketing authorisation for similar patient groups.

Ongoing combination trials continue to explore tafasitamab's potential to treat B-cell malignancies, although its efficacy and safety in these investigational indications have yet to be confirmed in trials.

Incyte CEO Hervé Hoppenot stated: “This new agreement with MorphoSys provides Incyte with exclusive global rights to tafasitamab and full control over its development and commercialisation, allowing us to realise significant operating efficiencies and cost synergies.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.